Tevogen.AI Applauds U.S. Government’s AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in Healthcare

Rhea-AI Summary

Tevogen (NASDAQ:TVGN) has expressed support for the White House's "Winning the Race: America's AI Action Plan" released on July 23, 2025. The company has developed PredicTcell™, an alpha version machine learning model, in partnership with Microsoft and Databricks.

The proprietary AI model is designed to significantly reduce target analysis time in immunotherapy research, potentially resulting in billions in cost savings for drug development. This aligns with the government's initiative to accelerate AI innovation and adoption in healthcare through domain-specific standards, regulatory sandboxes, and stakeholder convenings led by The National Institute of Standards and Technology.

The company, under CEO Ryan Saadi's leadership, emphasizes its commitment to developing scalable, ethical AI solutions to improve access to affordable advanced therapeutics.

Positive

• Development of PredicTcell™ AI model that reduces immunotherapy research time
• Strategic partnerships with major tech companies Microsoft and Databricks
• Potential for significant cost reduction in drug development process
• Alignment with government AI initiatives in healthcare

Negative

• PredicTcell™ is still in alpha version, indicating early development stage
• Need for additional capital to execute business plan
• Limited operating history as mentioned in risk factors

WARREN, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today welcomes the White House’s release of “Winning the Race: America’s AI Action Plan”, issued July 23, 2025. The Company applauds the federal government’s emphasis on establishing domain-specific standards, regulatory sandboxes (aka AI Centers of Excellence), and stakeholder convenings led by The National Institute of Standards and Technology to build trust, governance, and productivity in healthcare AI.

Aligned with AI Action Plan healthcare priorities, Tevogen.AI has recently developed the alpha version of PredicTcell™, a proprietary machine learning model built in collaboration with Microsoft (Nasdaq: MSFT) and Databricks. This model cuts weeks off target analysis in immunotherapy research, potentially saving billions in drug development costs. The approach reflects the Action Plan’s call for rapid scientific AI innovation and improved adoption of AI technology in the healthcare sector.

“As a mission-driven innovator, Tevogen.AI believes that AI has the potential to significantly reduce the cost and time required to bring life-saving treatments to patients in need,” said Ryan Saadi, MD, MPH, Founder and CEO of Tevogen. “We commend the U.S. government for recognizing this potential and setting a national strategy. With a focus on both innovation and equity, our work at Tevogen.AI seeks scalable, ethical solutions that expand access to affordable, advanced therapeutics for all Americans.”

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: that Tevogen will need to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s Annual Report on Form 10-K.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications

T: 1 877 TEVOGEN, Ext 701

Communications@Tevogen.com

FAQ

What is Tevogen's new AI technology PredicTcell™ and what does it do?

PredicTcell™ is a machine learning model developed with Microsoft and Databricks that accelerates target analysis in immunotherapy research, potentially saving billions in drug development costs.

How does Tevogen's AI initiative align with the U.S. government's AI Action Plan?

Tevogen's AI development aligns with the plan's focus on healthcare innovation, domain-specific standards, and regulatory sandboxes to build trust and productivity in healthcare AI.

Who are Tevogen's key partners in AI development?

Tevogen has partnered with Microsoft (NASDAQ: MSFT) and Databricks to develop its PredicTcell™ machine learning model.

What are the main challenges facing Tevogen's AI development plans?

Key challenges include need for additional capital, limited operating history, and potential regulatory hurdles as mentioned in their risk factors.

Who is leading Tevogen's AI initiatives?

The company's AI initiatives are led by Ryan Saadi, MD, MPH, who serves as Founder and CEO of Tevogen.